Caris Life Sciences announced a new AI‑powered molecular insight that helps oncologists decide whether adding chemotherapy to immunotherapy benefits or harms patients with non‑small cell lung cancer (NSCLC). The signature, built on the company’s CodeAI platform, combines whole‑exome sequencing, whole‑transcriptome sequencing and clinical data to stratify patients into higher‑ and standard‑risk groups and predict chemotherapy benefit.
The CodeAI platform, launched in October 2020, serves as a comprehensive informatics system that integrates molecular data with treatment outcomes. In this new insight, CodeAI processes WES and WTS data to identify genomic patterns that correlate with chemotherapy response, then overlays clinical variables to refine risk stratification. The result is a data‑driven recommendation that can reduce unnecessary toxicity and improve survival for driver‑negative, high‑PD‑L1 NSCLC patients.
Caris’s launch follows the FDA approval of its MI Cancer Seek tissue assay on November 6 2024 and the company’s ongoing expansion of its AI‑Insights portfolio. The new NSCLC signature adds to recent AI insights for pancreatic, breast and ovarian cancers, positioning Caris to deepen its footprint in the precision oncology market, which is projected to exceed $200 billion by 2030‑2034. The insight is available exclusively to Caris customers, potentially increasing utilization of its comprehensive profiling services.
Financially, Caris reported strong results in Q4 2025: total revenue of $292.9 million, a 125% year‑over‑year increase, and a gross margin of 75%, up 2,000 basis points from the prior year. Net income was $82.0 million. For full‑year 2025, revenue reached $812.0 million (97% YoY growth) with a gross margin of 66% and a net loss of $68.1 million, but adjusted EBITDA of $137.7 million and free cash flow of $66.9 million. Management projects full‑year 2026 revenue between $1.0 billion and $1.02 billion, maintaining positive free cash flow and adjusted EBITDA.
"The new NSCLC IO signature is an important step in personalizing NSCLC treatment and that not subjecting patients to potentially harmful chemotherapy is life‑changing," said David Spetzler, President of Caris. Founder, Chairman and CEO David Dean Halbert expressed excitement about the launch and the upcoming Caris Detect platform, slated for release in the first half of 2026.
The insight targets a specific patient subgroup—driver‑negative, high‑PD‑L1 NSCLC—where treatment options are limited. While the article does not quantify the prevalence of this group, the focus on a high‑risk, high‑PD‑L1 cohort underscores Caris’s strategy to address unmet clinical needs. Competitive solutions exist, but Caris’s signature is exclusive to its customers, giving the company a potential edge in a rapidly evolving therapeutic landscape.
Caris’s AI‑powered NSCLC insight strengthens its position in precision oncology, aligns with its financial momentum, and expands the commercial value of its profiling services. The launch is expected to drive higher utilization of Caris’s assays and support the company’s growth trajectory into the next decade.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.